BOOST Pharma

Revision as of 07:42, 14 April 2026 by Admin 3julmthh (talk | contribs) (Added valuation: €3.1M+ (Nov 2025); est. ~€5-15M)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Template:Company

What They Do edit

Cell therapy for children with osteogenesis imperfecta (genetic bone disease / brittle bone disease).

Funding edit

Valuation: €3.1M+ (Nov 2025); est. ~€5-15M €3.1 million additional funding (November 2025).^[1]

Traction edit

Strategic manufacturing agreement with RoslinCT for cell therapy production.^[2]

See Also edit

↑ EU-Startups (Nov 3, 2025): "In bid to improve outcomes for children with genetic bone disease, Swedish startup BOOST Pharma raises additional €3.1 million"
↑ BioSpace (2025): "RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement"

Retrieved from "https://wiki.stamen.health/index.php?title=BOOST_Pharma&oldid=248"